Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CDA | P32320 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22151854 | 0.81 | IRAK4 (0.45) | KMT2ACDAPDE7AIRAK4TSHR | |
| SCHEMBL1902496 | 0.80 | KDM4E (0.47) | EPHX1 | |
| SCHEMBL13395701 | 0.80 | IRAK4 (0.41) | KMT2ACDAPDE7AIRAK4L3MBTL1 | |
| SCHEMBL897372 | 0.78 | KMT2A (0.50) | KMT2ACDAPDE7AIRAK4TOP2A | |
| SCHEMBL6896207 | 0.78 | KMT2A (0.46) | KMT2ACDAPDE7AIRAK4L3MBTL1 | |
| SCHEMBL24521421 | 0.77 | TOP2A (0.43) | KMT2ACDAPDE7AIRAK4TSHR | |
| SCHEMBL14441585 | 0.77 | IRAK4 (0.44) | KMT2ACDAPDE7AIRAK4TSHR | |
| SCHEMBL23466508 | 0.77 | CDA (0.47) | KMT2ACDAPDE7AIRAK4TSHR | |
| SCHEMBL12309944 | 0.76 | KMT2A (0.49) | KMT2ACDAIRAK4TOP2ATOP2B | |
| SCHEMBL20808277 | 0.76 | L3MBTL3 (0.45) | L3MBTL1POLBTDP1L3MBTL3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3380474-B1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | KMT2A 1835/4885CDA 4170/4885PDE7A 907/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | KMT2A 2305/4885CDA 4387/4885PDE7A 755/4885 |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | KMT2A 947/4885CDA 4710/4885PDE7A 399/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | KMT2A 1835/4885CDA 4170/4885PDE7A 907/4885 |
| US-20220204517-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | KMT2A 947/4885CDA 4710/4885PDE7A 399/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KMT2A 2305/4885CDA 4387/4885PDE7A 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.